Symptom burden and quality of life in patients with high-risk essential thrombocythaemia and polycythaemia vera receiving hydroxyurea or pegylated interferon alfa-2a: a post-hoc analysis of the MPN-RC 111 and 112 trials

Analysis (2 studies; n=135 & 168) found in those with complete haematological response at 12 months after pegylated interferon alfa-2a, only 32% & 19% in 2 studies respectively had clinically significant reduction in symptoms (50% decrease in total symptom score based on MPN-SAF)